EW Price Prediction Next Week
Analysis and Insights
To predict the stock price of Edwards Lifesciences (EW) for the next trading week, we analyze both technical indicators and recent news sentiment.
Technical Analysis:
The current price of EW is $70.46, with a 14-day RSI of 47.37, indicating a neutral position. The MACD is slightly negative at -0.53, suggesting mild bearish momentum. Fibonacci resistance levels are at $71.32 (R1) and $72.39 (R2), while support is at $67.86 (S1).
News Sentiment and Fundamental Analysis:
EW reported strong Q4 earnings with a 9% sales increase, beating Wall Street estimates. Analysts maintain a "Moderate Buy" rating with a mean price target of $79.35, indicating a potential upside of 14.5% from current prices.
Conclusion:
Based on the analysis, the stock price of EW is expected to be around $70.63 next week. Considering the current technical indicators and news sentiment, it is recommended to sell or hold the stock as the potential upside appears limited compared to the downside risk.
EW Similar Chart Price Prediction
The price of EW is predicted to go up 9.76%, based on the high correlation periods with BK. The similarity of these two price pattern on the periods is 97.65%.
EW
BK
Up: 9.76%Similarity: 97.65%
EW Revenue Forecast
EW EPS Forecast
EW FAQs
What is EW revenue forecast for next quarter？
What is EW eps forecast for next quarter？
EW VS S&P500
Edwards' efforts to focus on efficiency and higher-margin products have paid off, as gross margins increased from 47% in 2000 to 77% in 2023.
Cardiothoracic surgeons are a fairly conservative bunch and like to stick with proven devices and brands. As a pioneer in heart valves, Edwards continues to be seen as the gold standard.
Edwards should benefit from an aging population, which experiences problems with heart valves and congestive heart failure with greater frequency.
EW Analyst's Forecast
Matt Miksic
Barclays
Buy
2025-02-13
Price Target
$88 → $90
Upside
+18.42%
Barclays analyst Matt Miksic raised the firm's price target on Edwards Lifesciences to $90 from $88 and keeps an Overweight rating on the shares post the Q4 report. The company reported "solid" 9% organic growth and upside to margins, which drove the earnings beat, the analyst tells investors in a research note. The firm expects the stock to continue to move higher driven by increased confidence in Edwards' intermediate and long-term growth goals, product launches, and clinical catalysts.
William Plovanic
Canaccord Genuity
Hold
2025-02-13
Price Target
$68 → $71
Downside
-6.58%
Adam Maeder
Piper Sandler
Hold
2025-02-12
Price Target
$70 → $73
Downside
-3.72%
